GNH USA

Europe — EMA

Levosimendan Bioglan

GNH USA supplies Levosimendan Bioglan (Levosimendan), a calcium sensitizer/inodilator for acute decompensated heart failure.

Levosimendan

Request sourcing

1
Pack/s

What is Levosimendan?

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer / inodilator presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Bioglan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Levosimendan used for?

Levosimendan is indicated for the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Severe left ventricular dysfunction: enhances myocardial contractility to support circulation. Post‑cardiac surgery low‑output syndrome: provides hemodynamic support during recovery.

What are the side effects of Levosimendan?

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may require intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced blood flow. - Anaphylactic reactions: rare allergic responses requiring emergency treatment.

What precautions apply to Levosimendan?

Use Levosimendan with careful clinical monitoring and consideration of patient‑specific factors.

Cardiovascular monitoring: observe blood pressure and heart rate continuously during infusion. Renal impairment: adjust therapy or monitor closely in patients with reduced kidney function. Hepatic impairment: use with caution in patients with liver disease. Concomitant vasodilators: may potentiate hypotensive effects; dose adjustments may be needed. Pregnancy: safety not established; avoid unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Levosimendan interact with?

Levosimendan can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - Phosphodiesterase inhibitors (e.g., milrinone): may increase arrhythmia risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response. - Calcium channel blockers: can affect hemodynamic stability. - ACE inhibitors or ARBs: monitor blood pressure for additive hypotension.

Frequently asked questions

What is Levosimendan Bioglan used for?+
Levosimendan Bioglan is used to treat acute decompensated heart failure. It provides inotropic support by increasing cardiac contractility and reduces vascular resistance through vasodilation, helping improve cardiac output and relieve symptoms of congestion in adult patients.
How does Levosimendan work?+
Levosimendan works by binding to troponin C, which sensitizes the heart muscle to calcium and strengthens each contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in blood‑vessel walls, causing vasodilation and lowering the workload on the heart.
What is the usual dose of Levosimendan Bioglan?+
The dose of Levosimendan Bioglan is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The medication is administered intravenously under medical supervision, and dosing regimens are individualized for each patient.
Is Levosimendan safe in pregnancy or breastfeeding?+
Safety data for Levosimendan in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the risk to the mother and fetus. Breastfeeding mothers should consult their healthcare provider.
How do I order Levosimendan Bioglan from GNH USA?+
To order Levosimendan Bioglan, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Levosimendan compare with other inotropes?+
Levosimendan differs from traditional catecholamine inotropes such as dobutamine because it increases contractility without raising intracellular calcium, reducing the risk of calcium‑mediated toxicity. Its vasodilatory effect also lowers afterload, whereas many other inotropes primarily increase heart rate and may cause more pronounced tachyarrhythmias.
How should Levosimendan be stored and handled?+
Levosimendan solution for injection should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken. During handling, avoid exposure to temperatures above the recommended range and ensure aseptic techniques are used for preparation and administration.
How is Levosimendan administered?+
Levosimendan is given as an intravenous infusion. The medication is typically diluted in a compatible solution and administered over a prescribed period under continuous cardiac and hemodynamic monitoring to ensure safety and therapeutic effectiveness.
What are the most serious risks associated with Levosimendan?+
Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood pressure drops, abnormal heart rhythms, and any signs of chest pain or allergic response throughout the infusion and afterwards.
Who should not use Levosimendan?+
Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant ventricular arrhythmias. Caution is also advised in patients with severe hepatic impairment or uncontrolled hypertension.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Levosimendan
Route
Intravenous Use
Manufacturer
Bioglan Ab
Origin
EU

Related products

Cordenova

Cordenova

Levosimendan

Orion Corporation
EU
Levatrop

Levatrop

Levosimendan

Pharmaselect International Beteiligungs Gmbh
EU
Levosimendan

Levosimendan

Levosimendan

Carinopharm Gmbh
EU
Levosimendan Accord

Levosimendan Accord

Levosimendan

Accord Healthcare B.V.
EU